Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicolas Girard

Showing results (221-230 of 396) with videos related to

Pageof 40
Sort By:
Molecular Oncology|October 21, 2022
Frequency, underdiagnosis, and heterogeneity of epidermal growth factor receptor exon 20 insertion mutations using real-world genomic datasetsSantiago Viteri, Anna Minchom, Lyudmila Bazhenova, et al.
Future Oncology (London, England)|October 26, 2023
Matching-adjusted indirect comparison of amivantamab vs mobocertinib in platinum-pretreated <i>EGFR</i> Exon 20 insertion-mutated non-small-cell lung cancerTae Min Kim, Nicolas Girard, Natasha B Leighl, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 16, 2016
Thymic Epithelial Tumor-Associated Cytopenia: A 10-Year Observational Study in FranceClaire Rivoisy, Benjamin Besse, Nicolas Girard, et al.
Diagnostic and Interventional Imaging|March 2, 2021
Intergroupe francophone de cancérologie thoracique, Société de pneumologie de langue française, and Société d'imagerie thoracique statement paper on lung cancer screeningSébastien Couraud, Gilbert Ferretti, Bernard Milleron, et al.
Annales De Pathologie|March 18, 2014
[Rythmic-pathology: the French national pathology network for thymic epithelial tumours]Lara Chalabreysse, Vincent Thomas De Montpreville, Anne De Muret, et al.
Clinical Lung Cancer|July 13, 2024
MDT-BRIDGE: Neoadjuvant Durvalumab Plus Chemotherapy Followed by Either Surgery and Adjuvant Durvalumab or Chemoradiotherapy and Consolidation Durvalumab in Resectable or Borderline-resectable Stage IIB-IIIB NSCLCMartin Reck, Ernest Nadal, Nicolas Girard, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 27, 2014
Lung cancer in combined pulmonary fibrosis and emphysema: a series of 47 Western patientsNicolas Girard, Sylvain Marchand-Adam, Jean-Marc Naccache, et al.
Biomedicines|September 23, 2022
Efficacy and Safety of Combined Brain Stereotactic Radiotherapy and Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer with Brain MetastasesJudith Porte, Caroline Saint-Martin, Thomas Frederic-Moreau, et al.
Lung Cancer (Amsterdam, Netherlands)|December 18, 2021
Surgical or medical strategy for locally-advanced, stage IIIA/B-N2 non-small cell lung cancer: Reproducibility of decision-making at a multidisciplinary tumor boardJuliette Mainguene, Clémence Basse, Philippe Girard, et al.
JTO Clinical and Research Reports|April 20, 2026
Long-Term Response and Survival in Extensive-Stage SCLC Receiving Atezolizumab Plus Chemotherapy in a Real-World Setting: IFCT-1905 CLINATEZOLionel Falchero, Karim Amrane, Benoît Godbert, et al.
Pageof 40

Showing results (221-230 of 396) with videos related to

Sort By:
Pageof 40
Molecular Oncology|October 21, 2022
Frequency, underdiagnosis, and heterogeneity of epidermal growth factor receptor exon 20 insertion mutations using real-world genomic datasetsSantiago Viteri, Anna Minchom, Lyudmila Bazhenova, et al.
Future Oncology (London, England)|October 26, 2023
Matching-adjusted indirect comparison of amivantamab vs mobocertinib in platinum-pretreated <i>EGFR</i> Exon 20 insertion-mutated non-small-cell lung cancerTae Min Kim, Nicolas Girard, Natasha B Leighl, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 16, 2016
Thymic Epithelial Tumor-Associated Cytopenia: A 10-Year Observational Study in FranceClaire Rivoisy, Benjamin Besse, Nicolas Girard, et al.
Diagnostic and Interventional Imaging|March 2, 2021
Intergroupe francophone de cancérologie thoracique, Société de pneumologie de langue française, and Société d'imagerie thoracique statement paper on lung cancer screeningSébastien Couraud, Gilbert Ferretti, Bernard Milleron, et al.
Annales De Pathologie|March 18, 2014
[Rythmic-pathology: the French national pathology network for thymic epithelial tumours]Lara Chalabreysse, Vincent Thomas De Montpreville, Anne De Muret, et al.
Clinical Lung Cancer|July 13, 2024
MDT-BRIDGE: Neoadjuvant Durvalumab Plus Chemotherapy Followed by Either Surgery and Adjuvant Durvalumab or Chemoradiotherapy and Consolidation Durvalumab in Resectable or Borderline-resectable Stage IIB-IIIB NSCLCMartin Reck, Ernest Nadal, Nicolas Girard, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 27, 2014
Lung cancer in combined pulmonary fibrosis and emphysema: a series of 47 Western patientsNicolas Girard, Sylvain Marchand-Adam, Jean-Marc Naccache, et al.
Biomedicines|September 23, 2022
Efficacy and Safety of Combined Brain Stereotactic Radiotherapy and Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer with Brain MetastasesJudith Porte, Caroline Saint-Martin, Thomas Frederic-Moreau, et al.
Lung Cancer (Amsterdam, Netherlands)|December 18, 2021
Surgical or medical strategy for locally-advanced, stage IIIA/B-N2 non-small cell lung cancer: Reproducibility of decision-making at a multidisciplinary tumor boardJuliette Mainguene, Clémence Basse, Philippe Girard, et al.
JTO Clinical and Research Reports|April 20, 2026
Long-Term Response and Survival in Extensive-Stage SCLC Receiving Atezolizumab Plus Chemotherapy in a Real-World Setting: IFCT-1905 CLINATEZOLionel Falchero, Karim Amrane, Benoît Godbert, et al.
Pageof 40